The primary reason Boston Scientific's TAVR valve fell short in clinical trial

The one-year outcomes presented as a late-breaking trial at the 2024 Transcatheter Cardiovascular Therapeutics (TCT) meeting showed the Boston …

Do you trust this headline?

Based on recent headline ratings, 90% of this readership currently trusts the local media, which has an average score of 80% regionally and is currently trending positive.

90%

Media Trust Score